Niagen Bioscience, Inc. (NAGE) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call shows strong financial performance, with significant revenue growth and improved net income. The strategic partnership and strong balance sheet are positive indicators. Despite some uncertainties in the Q&A, such as the new partnership's feedback and rollout timelines, the overall sentiment is positive due to the optimistic outlook on margins and potential market expansion. The absence of debt and increased cash flow bolster the positive sentiment. Without market cap data, a precise prediction is challenging, but overall indicators suggest a positive impact on the stock price.
Key Financial Performance
Revenue $34 million, a 33% increase year-over-year. The increase was driven by growth in e-commerce and distribution businesses.
Net Income $4.6 million compared to $1.9 million last year, showing a significant improvement. This was attributed to operational discipline and increased revenue.
Cash and No Debt $64.3 million in cash and no debt, reflecting a strong balance sheet.
E-commerce Net Sales $19 million, a 29% increase year-over-year, driven by growing awareness and demand for Niagen products.
Distribution Business Revenue $7 million, a 109% increase year-over-year, supported by a new strategic partnership with access to over 8,000 medical and health care practitioners.
Niagen Ingredient Business Revenue $6.9 million, remained steady with a 4% increase year-over-year.
Gross Margin 64.5%, up 100 basis points from 63.5% a year ago. The improvement was due to changes in product mix, better labor and overhead utilization, and lower cost inventory purchases.
Selling and Marketing Expense 25.8% of net sales, improved from 27.5% in the third quarter of 2024, reflecting efficient investments in global brand awareness.
Research and Development Expense $1.8 million, $0.5 million higher year-over-year, driven by continued investment in research and innovation.
General and Administrative Expenses $7.1 million, an $800,000 increase compared to the previous year, primarily due to increased share-based compensation expense.
Net Cash Provided by Operations $12.8 million for the 9 months ended September 30, 2025, compared to $3.5 million in the same period last year. The increase was driven by higher net income, improved collections on trade receivables, and higher accounts payable.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Niagen Plus at-home injection kits: Launched in August, available only with a prescription, with plans to expand distribution via telehealth and e-commerce.
Niagen ingredient business: Generated $6.9 million in revenue, steady performance.
Tru Niagen: Revenue grew by 44% to $26 million, driven by e-commerce and distribution.
New strategic partnership: Onboarded a partner with access to over 8,000 medical and healthcare practitioners, enhancing distribution and awareness.
iCRYO clinic network: Expanded to over 50 clinics nationwide, with more than 1,000 wellness and healthcare clinics offering Niagen Plus.
Asia Pacific expansion: Working with Watson's to strengthen Tru Niagen's presence in Hong Kong and launch in additional markets.
Revenue growth: Achieved $34 million in revenue, a 33% year-over-year increase.
Gross margin improvement: Improved to 64.5%, driven by product mix and cost efficiencies.
Cash position: Ended the quarter with $64.3 million in cash and no debt.
Scientific validation: Highlighted over 40 peer-reviewed clinical studies supporting Niagen's efficacy.
Regulatory challenges: Addressed FDA's reversal on NMN and emphasized Niagen's superior scientific validation.
NOPARK clinical trial: Phase III trial for Parkinson's disease completed, results expected in early 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Challenges: The FDA reversed a prior determination that nicotinamide mononucleotide (NMN) could not be lawfully marketed as a dietary supplement. This decision is expected to face strong opposition and further challenges, creating regulatory uncertainty. Additionally, companies selling NMN may be infringing on existing patents owned by Niagen Bioscience, leading to potential legal disputes.
Competitive Pressures: The NAD market is rapidly expanding, but it is crowded with brands making unverified claims and inconsistent product quality. This creates challenges for Niagen Bioscience to differentiate its scientifically validated products from competitors.
Supply Chain and Inventory Risks: Increased inventory levels to support operational expansion could lead to potential risks if demand does not meet expectations, resulting in excess inventory and associated costs.
Economic and Market Conditions: Global market and economic conditions could adversely impact the company's business, as highlighted in their quarterly report on Form 10-Q.
Strategic Execution Risks: The company is expanding its distribution network and launching new products like Niagen Plus at-home injection kits. However, these initiatives require effective execution to achieve desired outcomes, and any missteps could impact financial performance.
Litigation Risks: The company has challenged competitors making false claims about their NAD products. While this affirms Niagen's scientific rigor, it could lead to prolonged legal battles and associated costs.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth Guidance: Niagen Biosciences revised its revenue growth guidance for the full year 2025 from 22%-27% to 25%-30% year-over-year, supported by strong e-commerce performance and partnerships in the expanding NAD market.
Research and Development Expenses: The company expects R&D expenses to decline as a percentage of net sales while still increasing in absolute dollars, reflecting changes in the timing of studies and projects.
General and Administrative Expenses: General and administrative expenses are projected to increase by $8 million to $9 million in absolute dollars year-over-year, driven primarily by increased share-based compensation expense.
Phase III NOPARK Clinical Trial: Results from the Phase III NOPARK clinical trial for Parkinson's disease are expected to be published in early 2026.
Expansion of Niagen Plus Distribution: Plans to expand the distribution of Niagen Plus at-home injection kits via a telehealth platform and e-commerce channels to reach more patients.
New Partnerships: A new strategic partner provides access to over 8,000 medical and healthcare practitioners, enhancing Tru Niagen distributor revenues and awareness.
NAD Market Growth: The NAD market is rapidly expanding, with opportunities in supplements, injections, skincare, cosmetics, food, beverages, and drug applications.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the uptake and feedback from clinics regarding the new IV partnership?
A:The purchase was made towards the end of the quarter, and the process of reselling the material to their physician network has just begun. No direct feedback has been received yet.
Q:Where does the AboutNAD website fit in the marketing funnel?
A:The AboutNAD website is an objective information resource for journalists, investors, researchers, and others interested in NAD science. It is not connected to the purchasing funnel and does not promote products.
Q:Are at-home injection kits available in all physician offices, and what is the rollout plan?
A:At-home kits are currently available only in clinics, and the user experience is still being optimized. The kits are expected to be available on the company’s website in several months. Telehealth functionality for prescriptions and delivery is expected by mid-next year.
Q:Are there multiple telehealth platforms being engaged for at-home injection kits?
A:Yes, the company is in discussions with multiple telehealth platforms.
Q:Has the FDA's announcement on NMN affected consumer purchasing behavior?
A:No significant changes in consumer purchasing behavior have been observed since the FDA announcement. The market remains dominated by smaller companies and Chinese manufacturers, with many products not meeting label claims.
Q:Is there a plan to establish a stand-alone entity for pharmaceutical applications of nicotinamide riboside?
A:Yes, it is likely. The company is waiting for study results and discussions with pharma companies to determine the timing and structure of the entity. Segment reporting may begin in the next quarter or two.
Q:What is the market size and potential for Niagen Plus IV and injection products?
A:The market includes 2,000-3,000 IV clinics, several thousand physicians, and potentially 10,000 offices including Botox clinics. The injection market, particularly telehealth, is seen as a larger opportunity. However, high consumer prices are a barrier to significant growth.
Q:Has the FDA decision on NMN affected pricing discussions with ingredient partners?
A:No significant impact on pricing discussions has been observed. Ingredient partners continue to request price reductions regardless of the FDA decision.
Q:Why was the gross margin higher than expected, and what is the outlook?
A:The higher gross margin was due to leftover lower-cost inventory and improved product mix. Margins are expected to normalize but still show improvement compared to last year.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers or lacked clarity on the following: 1. Uptake and feedback from clinics regarding the new IV partnership, citing it was too early for feedback. 2. Specific details on the rollout timeline and user experience optimization for at-home injection kits. 3. Exact timing and structure for establishing a stand-alone entity for pharmaceutical applications, pending study results and discussions. 4. Quantification of the market size and timeline for reaching steady-state penetration for Niagen Plus IV and injection products, citing high consumer prices as a barrier.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Advertising Division
Advertising division
Better Bureau
Bio challenge
Bioscience Inc
Bioscience market
Bioscience rigor
Bureau position
COVID study
Director
Dr
Inc Conference
NR supplementation
National Advertising
Niagen Bioscience
Niagen Plus
QA
care practitioner
cell NAD
decision
drug application
effect NR
health care
home injection
injection kit
network
patient
peer study
progress
review
study NAD
symptom
NAGE Transcript
Niagen Bioscience, Inc. (NAGE) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call reveals strong financial performance, with 12% revenue growth and improved margins. The company projects continued growth through new product launches and market expansions. Despite regulatory and market expansion risks, the optimistic guidance and strategic initiatives, such as increased R&D and capital expenditures, suggest positive sentiment. The absence of negative sentiment in the Q&A further supports this view. Overall, the positive financial results and forward-looking strategies indicate a likely positive stock price movement in the short term.
Niagen Bioscience, Inc. (NAGE) Q4 2025 Earnings Call Transcript
Positive3-4
The earnings call highlights strong financial performance with a 30% YoY revenue growth and improved net income and gross margin. The company has no debt and substantial cash reserves, indicating financial stability. Positive factors include a new partnership expanding distribution, a conservative yet confident guidance, and a $10 million share buyback plan. Although there are some uncertainties, such as legal issues with the FDA, the overall sentiment is positive, driven by strong financials and strategic growth initiatives.
Niagen Bioscience, Inc. (NAGE) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call shows strong financial performance, with significant revenue growth and improved net income. The strategic partnership and strong balance sheet are positive indicators. Despite some uncertainties in the Q&A, such as the new partnership's feedback and rollout timelines, the overall sentiment is positive due to the optimistic outlook on margins and potential market expansion. The absence of debt and increased cash flow bolster the positive sentiment. Without market cap data, a precise prediction is challenging, but overall indicators suggest a positive impact on the stock price.
Niagen Bioscience Inc (NASDAQ:NAGE) Q1 2025 Earnings Call Transcript
Positive5-14
The earnings call presented robust financial performance with a 38% revenue increase and a $5.1 million net income. The company has a strong cash position with no debt and has initiated a $10 million share buyback program. Despite some regulatory uncertainties, the strong growth in e-commerce and ingredient business, coupled with strategic market expansion plans, and positive product reception indicate a strong positive sentiment. The lack of market cap data suggests potential for a strong stock price reaction.
NAGE Slides
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
